PAULSON & COMPANY . INC.

recently revealed that they own a 6% stake in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a Schedule 13D disclosure that was filed with the Securities and Exchange Commission on Wednesday, August 9th. The investor owns 20,839,038 shares of the stock worth approximately $293,205,265. The disclosure is available through EDGAR at this hyperlink.

PAULSON & COMPANY . INC.

provided the following explanation of their ownership:

Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6

Warning: file_get_contents(https://whalewisdom.com
20,839,038
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6

Other large investors have also recently modified their holdings of the company. ValueAct Holdings L.P. increased its stake in shares of Valeant Pharmaceuticals International by 20.0% in the first quarter. ValueAct Holdings L.P. now owns 17,997,224 shares of the specialty pharmaceutical company’s stock valued at $198,509,000 after buying an additional 3,002,963 shares in the last quarter. Canada Pension Plan Investment Board increased its stake in shares of Valeant Pharmaceuticals International by 24,953.6% in the second quarter. Canada Pension Plan Investment Board now owns 2,104,500 shares of the specialty pharmaceutical company’s stock valued at $36,525,000 after buying an additional 2,096,100 shares in the last quarter. Saba Capital Management L.P. increased its stake in shares of Valeant Pharmaceuticals International by 132.4% in the first quarter. Saba Capital Management L.P. now owns 2,315,900 shares of the specialty pharmaceutical company’s stock valued at $25,544,000 after buying an additional 1,319,311 shares in the last quarter. Cannell Peter B & Co. Inc. bought a new stake in shares of Valeant Pharmaceuticals International during the second quarter valued at about $20,981,000. Finally, Bogle Investment Management L P DE bought a new stake in shares of Valeant Pharmaceuticals International during the first quarter valued at about $11,223,000. 51.14% of the stock is owned by hedge funds and other institutional investors.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) traded down 10.04% during trading on Wednesday, reaching $14.07. 39,119,510 shares of the company’s stock traded hands. The company’s 50 day moving average is $16.44 and its 200-day moving average is $13.39. Valeant Pharmaceuticals International, Inc. has a 52-week low of $8.31 and a 52-week high of $32.74. The stock’s market cap is $4.90 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 58.02% and a negative net margin of 14.96%. The company had revenue of $2.23 billion during the quarter, compared to analyst estimates of $2.23 billion. During the same quarter last year, the firm posted ($0.88) earnings per share. The firm’s revenue was down 7.7% on a year-over-year basis. On average, analysts anticipate that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/paulson-company-inc-declares-ownership-of-stake-in-valeant-pharmaceuticals-international-inc-nysevrx/1466273.html.

VRX has been the subject of several research reports. Wells Fargo & Company reissued an “underperform” rating on shares of Valeant Pharmaceuticals International in a research report on Monday, June 12th. J P Morgan Chase & Co reissued a “hold” rating on shares of Valeant Pharmaceuticals International in a research report on Tuesday, May 9th. Zacks Investment Research downgraded shares of Valeant Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 13th. BidaskClub raised shares of Valeant Pharmaceuticals International from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Finally, TD Securities lowered their price objective on shares of Valeant Pharmaceuticals International from $18.50 to $15.00 and set a “hold” rating for the company in a research report on Wednesday, May 10th. Four research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Valeant Pharmaceuticals International presently has an average rating of “Hold” and an average price target of $17.26.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, May 11th. The stock was bought at an average price of $13.90 per share, with a total value of $278,000.00. Following the completion of the purchase, the director now directly owns 70,572 shares of the company’s stock, valued at approximately $980,950.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.87% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.